Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10667)	7/8/1999 12:56:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 17367

Today's issue of BioWorld has a short article on the hu1124 release. Your friend Ellen M. is cited: (1) ".. plan now is to move hu1124 into a phase III program, likely in the fourth quarter." (2) ".. we are considering additional indications. Psoriasis has become a very interesting model for testing T-cell-mediated drugs." (3) "I think we have the advantage of a good mechanism and an early start. Of course, Genentech as a partner is hard to beat." (4) "It is not clear at this time whether there will be one or more trials required. We are also looking at alternative forms of administration." (my comment: IV is not the most convenient form; subcutaneous would be advantageous.) (5) Among the T-cell-mediated chronic inflammatory disorders expected to be considered for future testing are RA, MS and inflammatory bowel disease (IBD). (my comment: this last point is NOT a direct Martin quote) BTW, who are "the real experts"? PB